• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.

    8/12/25 10:34:24 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRNX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Crinetics Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    22663K107

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    22663K107


    1Names of Reporting Persons

    Wellington Management Group LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,879,998.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,807,308.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,807,308.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.2 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    22663K107


    1Names of Reporting Persons

    Wellington Group Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,879,998.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,807,308.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,807,308.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.2 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    22663K107


    1Names of Reporting Persons

    Wellington Investment Advisors Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,879,998.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,807,308.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,807,308.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.2 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    22663K107


    1Names of Reporting Persons

    Wellington Management Company LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,854,961.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,424,163.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,807,308.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Crinetics Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    6055 Lusk Blvd, San Diego CA 92121
    Item 2. 
    (a)Name of person filing:

    Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
    (b)Address or principal business office or, if none, residence:

    c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
    (c)Citizenship:

    Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    22663K107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.
    (b)Percent of class:

    6.20  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See the responses to Item 8 on the attached cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Wellington Management Group LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:08/12/2025
     
    Wellington Group Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:08/12/2025
     
    Wellington Investment Advisors Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:08/12/2025
     
    Wellington Management Company LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:08/12/2025
    Get the next $CRNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRNX

    DatePrice TargetRatingAnalyst
    7/10/2025$36.00Neutral
    Goldman
    3/25/2025$60.00Buy
    Stifel
    2/11/2025Buy
    TD Cowen
    2/4/2025Peer Perform
    Wolfe Research
    1/22/2025$55.00Hold → Buy
    Jefferies
    3/6/2024$68.00Buy
    Citigroup
    1/16/2024$50.00Overweight
    Morgan Stanley
    12/21/2023$35.00Hold
    Jefferies
    More analyst ratings

    $CRNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an aggregate of 53,400 restricted stock unit ("RSU") awards to 27 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(

    8/11/25 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

          Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date       Continued Progress on the Global Development Program for Atumelnant Across Multiple Trials, Including the BALANCE-CAH Phase 2/3 Study for the Treatment of Children with Congenital Adrenal Hyperplasia Expected to Initiate this Year       $1.2B in Cash, Cash Equivalents, and Investment Securities as of June 30, 2025 Anticipated to Provide Runway into 2029       Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a

    8/7/25 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

    SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, August 7 @ 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 404-975-4839Access Code: 899803    Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommen

    7/11/25 8:00:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Betz Stephen F. exercised 88,170 shares at a strike of $3.30 and sold $3,141,877 worth of shares (97,483 units at $32.23), decreasing direct ownership by 9% to 99,713 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    6/16/25 4:48:09 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Deardorf Caren was granted 6,900 shares, increasing direct ownership by 73% to 16,300 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    6/13/25 4:30:20 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Okey Stephanie was granted 6,900 shares, increasing direct ownership by 73% to 16,300 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    6/13/25 4:30:20 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    SEC Filings

    View All

    $CRNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.

    SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    8/12/25 10:34:24 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Crinetics Pharmaceuticals Inc.

    10-Q - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

    8/7/25 4:39:31 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

    8/7/25 4:38:34 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Crinetics Pharmaceuticals with a new price target

    Goldman initiated coverage of Crinetics Pharmaceuticals with a rating of Neutral and set a new price target of $36.00

    7/10/25 8:53:33 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Crinetics Pharmaceuticals with a new price target

    Stifel initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    3/25/25 8:26:55 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Crinetics Pharmaceuticals

    TD Cowen initiated coverage of Crinetics Pharmaceuticals with a rating of Buy

    2/11/25 7:03:38 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Leadership Updates

    Live Leadership Updates

    View All

    Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

    SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. "I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crineti

    2/24/25 8:30:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

    SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company's commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the company's deep, innovative pipeline of candidates. "Isabel is a highly accomplished leader with broad commercial expertise ranging from launching therapies to leading early-stage commercial strategy," said Scott Struthers, Ph.D

    12/16/24 8:00:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

    SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs. "Dr. Cuddihy's wealth of knowledge and experience both as a practicing physician in endocrinology and working within the pharmaceutical industry is an invaluable addition to our talented scientific leadership team," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "As we forg

    5/30/24 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 7:55:29 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 5:46:54 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Crinetics Pharmaceuticals Inc.

    SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 1:22:38 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Financials

    Live finance-specific insights

    View All

    Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

          Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date       Continued Progress on the Global Development Program for Atumelnant Across Multiple Trials, Including the BALANCE-CAH Phase 2/3 Study for the Treatment of Children with Congenital Adrenal Hyperplasia Expected to Initiate this Year       $1.2B in Cash, Cash Equivalents, and Investment Securities as of June 30, 2025 Anticipated to Provide Runway into 2029       Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a

    8/7/25 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

    SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, August 7 @ 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 404-975-4839Access Code: 899803    Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommen

    7/11/25 8:00:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

    Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date   CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal Hyperplasia to Initiate with Uncompromising Primary Endpoint to Normalize Androstenedione Levels with Physiologic Glucocorticoid Replacement R&D Day Scheduled for June 26 to Share Early-Stage Pipeline Strategy and Data $1.3B in Cash, Cash Equivalents, and Investment Securities as of March 31, 2025 Anticipated to Provide Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Crin

    5/8/25 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care